United States: FDA Finalizes Rule Governing Establishment Registration And Listing For Human Drugs

Summary

On August 31, 2016, the US Food and Drug Administration published "Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Including Drugs That Are Regulated Under a Biologics License Application, and Animal Drugs," finalizing a 2006 proposal to amend regulations governing drug establishment registration and listing.

In Depth

On August 31, 2016, the US Food and Drug Administration (FDA) published "Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Including Drugs That Are Regulated Under a Biologics License Application, and Animal Drugs" (Final Rule), finalizing a 2006 proposal (Proposed Rule) to amend regulations governing drug establishment registration and listing 71 Fed. Reg. 51,276 (Aug. 29, 2006). The Final Rule is effective November 29, 2016, and brings FDA's regulations governing drug establishment and listing in conformity with amendments to Section 510 of the Federal Food, Drug, and Cosmetic Act (FDCA) (described below), while modernizing submission requirements to maintain consistency with current electronic practices. These changes aim to improve efficiency and reliability. Under the Final Rule, establishment registration drug listing information is generally subject to inspection and public disclosure.

Notably, the Final Rule (1) gives FDA the authority to refuse a new drug application if it is manufactured in whole or in part in an establishment that is not registered or exempt under FDCA, and (2) requires holders of Biologics License Applications (BLA) to electronically report when they withdraw from the sale of licensed biological products.

After FDA issued the Proposed Rule, US Congress passed the Food and Drug Administration Amendments Act (FDAAA) in 2007, which required the electronic submission of drug establishment registration and listing information [Pub. L. 110–85 (2007)], and the Food and Drug Administration Safety and Innovation Act (FDASIA) in 2012, which amended the deadline for and information required with an annual establishment registration [Pub. L. 112–144 (2012)]. FDA subsequently issued its "Guidance for Industry on Providing Regulatory Submissions in Electronic Format—Drug Establishment Registration and Drug Listing" 74 Fed. Reg. 26, 248 (June 1, 2009) to explain electronic submissions of registration and listing information consistent with the FDAAA 71 Fed. Reg. 63,276 (Oct. 31, 2006).

The Final Rule includes few departures from the Proposed Rule. In response to comments, FDA did not include the requirement that FDA develop National Drug Codes (NDCs) to assign to listed drugs or the requirement that the NDC appear in human-readable form on the label of each listed drug. FDA indicated that it expects to address drug / device combination product registration and listing requirements in the future.

The remainder of this article highlights additional provisions.

Who Does the Rule Cover?

  • The Final Rule regulates domestic and foreign drug manufacturers, repackers, relabelers and salvagers, and requires annual electronic registration and listing, while carving out exemptions (e.g., certain "import for export" drugs). The Final Rule also covers establishments engaging in these activities under a BLA or human cells, tissues, and cellular and tissue-based products (HCT/Ps) regulated under Section 505 of the FDCA or under Section 351 of the Public Health Service Act.
  • FDA will accept registration and listing information from anyone properly authorized to act as an agent for the actual manufacturer, including private label distributors.
  • It is particularly important to note that the drug listing requirement applies to drugs manufactured, repacked, relabeled or salvaged for commercial distribution only, while the registration requirement applies to establishments where drugs are manufactured without regard to whether the drug is commercially distributed.

Content of Registration and Listing

  • The Final Rule includes specific content requirements for registration and listing. Pursuant to the FDASIA, the Final Rule amends the registration requirements to include a Unique Facility Identifier (UFI), which is currently a DUNS number, assigned and managed by Dun & Bradstreet. The FDASIA also requires establishments to provide a point-of-contact email address.
  • Because FDA's drug listing system cannot retrieve inactive ingredient information from approved applications, a registrant must provide the name of each inactive ingredient in a listed drug it manufactures—the drug's US application number will not suffice. Although FDA is not currently collecting advertisements as part of drug listing information, it may request a representative sampling of advertisements in the future.
  • The Final Rule includes additional NDC requirements, such as format, length, changes requiring a new NDC and restrictions.
  • Under the Final Rule, FDA's center directors may now approve additional standards or formats for bar code label requirements.

Effective Dates

  • Electronic registration and listing submissions under Part 207 have largely been implemented under FDA's Guidance. As of November 29, 2018, to purge outdated information, FDA will remove from the current database any previous registration and listing information submitted in the past on paper and not updated with a more recent electronic submission. However, FDA may grant firms waivers from the electronic submission requirement. The requirement for electronic registration and listing under Parts 607 and 1271 for drugs regulated under a BLA or HCT/Ps regulated under Section 505 of the FDCA or Section 351 of the Public Health Service Act, respectively, will be effective November 29, 2017.
  • FDA encourages establishments to submit listing updates at the time of any change affecting the previously submitted information, and at a minimum, each June and December. As part of the annual registration process, establishments also must submit a no-change certification if there are no changes to the previously submitted listings.

Addition and Clarification to Definitions

  • "Active pharmaceutical ingredient" has the same meaning as "bulk drug substance."
  • "Salvage" means "the act of segregating out those finished products that may have been subjected to improper storage conditions for the purpose of returning the products to the marketplace and includes applying manufacturing controls such as current good manufacturing practice (CGMP)."
  • Establishment registration number" means the number assigned by FDA to the establishment during the establishment registration process [currently, the FDA Establishment Identifier (FEI)] and is distinct from the "Unique Facility Identifier" required by the FDASIA).
  • Clarifying "commercial distribution" to exclude "active pharmaceutical ingredient" so internal or interplant transfers are not treated as commercial distribution. Transfers between a registered establishment and a marketing authorization holder pursuant to a contractual relationship still constitute commercial distribution.
  • Content labeling" is used to describe some, but not all, labeling that must be submitted with human and animal drug listing information.
  • A "private label distributor," whose label or trade name is on a commercially distributed drug, does not have to register or list as long as it does not manufacture, repack, relabel or salvage a drug. Private label distributors still must apply for a NDC labeler code.
  • A drug's "end marketing date" is the expiration date of the last lot manufactured, repacked, relabeled or salvaged and should be included when reporting that a listed drug has been discontinued.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.